AbbVie, Danaher, Vertex Pharmaceuticals, Cencora, GSK, Thermo Fisher Scientific, and Moderna are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks ...
Swiss biotech BioVersys, which develops treatments for serious infections caused by drug resistant bacteria, has completed its initial public offering with an implied market valuation of 213 million ...
The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...
The stock market extended its winning streak on Wednesday, closing firmer as investors seemed to have already priced in the ...
Q4 2024Management ViewCEO Dame Emma Walmsley highlighted that GSK achieved 8% sales growth in 2024, reaching over ...
A summary of the latest financial news from European markets, including stock performance, unemployment rates, trade surplus, bond yields, and ...
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Zacks.com on MSN2d
GSK Beats on Q4 Earnings & Sales, Stock Up on Raised Long-Term OutlookGSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...
GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments.
GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...
GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...
GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback